Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$4.44 USD
-0.07 (-1.55%)
Updated May 17, 2024 04:00 PM ET
After-Market: $4.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SMMT 4.44 -0.07(-1.55%)
Will SMMT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SMMT based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SMMT
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
Summit spikes as Citi launches at Buy on lead asset
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
Target upgraded, CVS downgraded: Wall Street's top analyst calls
Target upgraded, CVS downgraded: Wall Street's top analyst calls